Vigil Neuroscience's (VIGL) Market Outperform Rating Reiterated at JMP Securities

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report)'s stock had its "market outperform" rating reaffirmed by analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $22.00 target price on the stock.

Several other equities research analysts have also issued reports on VIGL. Wedbush upped their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Friday, November 8th. Finally, Guggenheim lowered their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.60.

Vigil Neuroscience Stock Performance

Shares of VIGL stock traded down $0.18 during trading hours on Tuesday, hitting $3.01. 101,076 shares of the company were exchanged, compared to its average volume of 228,591. The stock has a market capitalization of $123.05 million, a price-to-earnings ratio of -1.46 and a beta of 1.92. Vigil Neuroscience has a one year low of $2.47 and a one year high of $6.06. The business's 50-day simple moving average is $3.49 and its two-hundred day simple moving average is $3.67.

Institutional Trading of Vigil Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock valued at $3,050,000 after acquiring an additional 95,276 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at $26,000. Renaissance Technologies LLC boosted its stake in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock valued at $286,000 after buying an additional 11,536 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vigil Neuroscience in the 2nd quarter worth approximately $87,000. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.